Human antibodies for immunohistochemical analysis of prostate cancerTechnology #2739
Questions about this technology? Ask a Technology Manager
This technology describes polyclonal antibodies for immunohistochemical analysis of prostate carcinoma tissues.
Unmet Need: Improved detection of prostate cancer
Early detection of prostate cancer is key to successful treatment. Current methods for detection of cancer typically require a physical exam or the detection of prostate-specific antigen (PSA) in the blood. However, a biopsy is often still needed to confirm diagnosis and determine treatment options. As such, there is a need for targeted antibodies for immunohistochemical analysis that can diagnose and classify prostate cancer for personalized treatment.
The Technology: Human anti-Nkx3.1 antibodies enable detection of cancer in prostate tissue
This technology provides polyclonal antibodies against the Nkx3.1 homeobox gene product for targeted detection and analysis of prostate carcinoma tissues. Loss of function of NKx3.1 in mice is associated with loss of function of the Pten tumor suppressor gene linked to cancer progression. Consequently, the absence of NKx3.1 protein expression may indicate early human prostate carcinogenesis and could be employed as a diagnostic test for prostate cancer. This technology provides antibodies against Nkx3.1 that could be used for diagnosing loss of NKx3.1 expression in immunohistochemical analysis or other bioassays.
- Immunohistochemical analysis of prostate carcinomas
- Detection and characterization of prostate cancer
- Provides a direct assay against the Nkx3.1 protein involved in cancer initiation
- Compatible with existing immunohistochemical methods
Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate-Shen C. “Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation” Science. 2016 Jun 24; 352(6293): 1576-80.
Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. “Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis” PNAS. 2002 Mar 5; 99(5): 2884-9.
Tech Ventures Reference:
Licensing Contact: Joan Martinez